Toripalimab
Coherus,Junshi Biosciences
['toripalimab', 'ts,perio,i', 'lcsm,(-blcsm)']
periop toripalimab + platinum-doublet v chemo in resectable stage ii/iii improved efs w/ higher mpr (48.5%) and pcr rates (24.8%) compared to chemotherapy alone in stage iii. benefits non-sq and sq : the hrs 0.54 v 0.35. #asco23 #lcsm 
#HemeOnc @LombardiCancer |@EmoryDeptofMed @GradyHealth @tulanemedicine |#MedEd #clinicaltrials #disparities #lcsm 🎶🎤|🐱mom|she/her⚜️🏠#504 tweetsmyown